(EMAILWIRE.COM, November 18, 2009 ) Dallas, TX - Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) climbed 33% to $2.43 on over 2.43 million shares after it announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, given once every four weeks in combination with five fluorouracil and leucovorin in the FOLPI regimen, has comparable efficacy to oxaliplatin, given in combination with five fluorouracil and leucovorin in the modified FOLFOX-6 regimen, as a first-line therapy for CRC, as assessed by one-year survival rate, progression-free survival (PFS) and disease control

Cell Therapeutics, Inc. (NASDAQ:CTIC) was one of the top gainers and rallied 6.93% to closed at $1.08 on over 12.07 million shares. The stock hit an intraday high and low of $1.09 and $1.05 respectively. So far this year the stock has rallied over 723%. Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer.

VIVUS, Inc. (NASDAQ:VVUS) was one of the most active stocks as it gained over 9.30% to end the day at $8.57 on huge volume of 5.69 million shares. The stock hit an intraday high and low of $8.68 and $7.78 respectively. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products.

ABOUT http://www.PennyStockPickalert.com

Penny Stock Pick Report is an independent electronic publication that provides information on selected publicly traded companies. Penny Stock Pick Report is not a registered investment advisor or broker-dealer. Penny Stock Pick Report affiliates, directors, officers, and employees may purchase and sell additional shares in any company which are mentioned above and may profit in the event those shares rise in value. Please do your research before you plan to invest in any of the stocks mentioned above.

Contact Information:
PennyStockPickAlert.com
Robert Wilson
Tel: 214 556 6798
Email us